Adding the experimental oral therapy voclosporin to standard treatment is safe, and its use more than doubles complete kidney responses…
Articles by Patricia Inacio, PhD
More stringent thresholds in the Cutaneous Lupus Activity and Severity Index (CLASI), a common tool to assess disease progression…
While people with systemic lupus erythematous lupus (SLE) are experiencing fewer eye complications directly linked to the disease, treatment-induced…
Elevated blood levels of a marker called galectin-9 may help identify people with systemic lupus erythematous lupus (SLE) who…
Hardening of the kidney arteries, a condition called renal arteriosclerosis, is detected two decades earlier in people with…
Levels of proteins associated with changes in the inner wall of blood vessels — the endothelium —  are higher in…
People with systemic lupus erythematosus (SLE) who stop treatment with hydroxychloroquine less than 12 months after its start…
More than 40% of systemic lupus erythematosus (SLE) patients do not comply with hydroxychloroquine (HCQ) therapy, even among…
A Phase 3 trial assessing the potential of voclosporin as an add-on to standard treatment for people with…
Apellis Pharmaceuticals has decided to stop the development of an experimental therapy known as APL-2 for lupus…